Contract immunoassay development for early cancer detection

Biofortuna have signed a long-term contract to provide contract research and development to a leading early cancer detection company. This relationship will lead to the commercialisation of an ELISA based oncology assay.

Biofortuna will be providing:

Design and development consultancy of immunoassay technologies.
Expertise in ELISA reaction stabilisation methods.
Full validation and verification testing.
Technology transfer of small scale manufacturing procedures to full-scale commercialisation manufacturing protocols.
A potential manufacturing partner with a thorough understanding of the underlying technologies.

The client is now routinely manufacturing with Biofortuna to satisfy increased demand of its CE-marked kits.

Back